Despite the routine use of antibiotics, corticosteroids, and nonsteroidal anti-inflammatory (NSAID) agents in postoperative ophthalmic surgical care, there remain issues with drug delivery of these agents. Ongoing education about novel corticosteroids and technologies is warranted to ensure eye care providers can deliver the best patient care possible.
All education activities identified in this education design document will be targeted to ophthalmologists and optometrists. The following categories of doctors have been identified as those with the greatest need for this educational intervention:
I. Ophthalmologists who perform ophthalmic surgery.
II. Ophthalmologists involved in the management of ocular inflammation following ophthalmic surgery.
III. Optometrists who comanage patients following cataract surgery.
Supported through an independent educational grant from Ocular Therapeutix.
This initiative is designed to address and resolve the educational needs through the following educational objectives:
Provided by Evolve Medical Education
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring. material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Evolve is an approved COPE Administrator.
This course is COPE approved for .5 hour of CE credit for optometrists.
Leon W. Herndon Jr., MD
Professor of Ophthalmology
Chief of Glaucoma Division
Duke Eye Center
Durham, North Carolina
Sydney L. Tyson, MD, MPH
President, Eye Associates and SurgiCenter
Vineland, New Jersey
Attending Surgeon, Board of Directors, and Treasurer
Cataract Primary Eye Care Service Ltd.
Wills Eye Hospital
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Sydney L. Tyson, MD, MPH and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon and Ocular Therapeutix. Grant/Research Support: Glaukos and Ocular Therapeutix. Speaker’s Bureau: Alcon and Ocular Therapeutix.
Leon W. Herndon, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, New World Medical, Ocular Therapeutix, and Santen. Grant/Research Support: Glaukos. Stock/Shareholder: Sight Sciences.
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Ocular Therapeutix.